Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: A single-center study

Table 1 Patient characteristics at transplant n (%)

Median age (range)	56 (18-72)
Sex, M/F	198/129
Diagnosis
Multiple myeloma	201 (61)
B-cell non-Hodgkin's lymphoma	80 (25)
Hodgkin's lymphoma	27 (8)
T-cell non-Hodgkin's lymphoma	19 (6)
CMV IgG seropositivity1	304 (93)
HBcIgG serositivity	46 (14)
HCVAb seropositivity1	5 (1.5)
Disease status
Complete response	205 (63)
Partial response	114 (35)
Stable/progressive disease	8 (2)
Prior chemotherapy lines
1	185 (57)
2	120 (37)
≥ 3	22 (6)
Prior fludarabine treatment	5 (1.5)
Prior alemtuzumab treatment	0
Conditioning regimen
BEAM or BEAM-like	126 (39)
MEL200/MEL100	201 (61)
Median CD34+ infused cells × 106/kg (range)	5.62 (2.36-28.48)

¹Datum is missing in 2 patients. BEAM: Carmustine, Etoposide, Cytarabine, Melphalan; MEL200: Melphalan 200 mg/m²; MEL100: Melphalan 100 mg/m²; CMV: Cytomegalovirus.